Search

Elixir Medical Announces Outstanding 24-Month Data for DynamX Coronary Bioadaptor System, Demonstrating Strong Safety With No Target Lesion Revascularization, Myocardial Infarction Or Thrombosis Through 24 Months

Successful DynamX Bioadaptor Live Case Presented at Singapore Live MILPITAS, Calif. – January 27, 2020 – Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced the 24-month clinical results for the DynamX™ Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology. The results were presented at the 30th Annual Live Interventions in Vascular […]

Elixir Medical Announces Outstanding 12-Month Data for DynamX Coronary Bioadaptor System, Demonstrating No Target Vessel Revascularization, No Thrombosis and Positive Adaptive Remodeling of the Artery

PARIS – June 25, 2020 — Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System, the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on the Main Arena channel of the PCR e-Course as part of the […]

Elixir Medical Corporation Announces Outstanding 5-Year Clinical Data for CE Mark-Approved DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System

Excellent Six-Month Safety and Efficacy Results for Next-Generation Thin-strut DESolve® Cx Novolimus Eluting Bioresorbable Coronary Scaffold System also presented Milpitas, CA – May 17, 2017 — Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, today announced excellent 5-year clinical data from the DESolve Nx international pivotal clinical trial for the CE Mark-approved, […]

Elixir Medical Corporation Announces Excellent Six-Month Safety and Efficacy Results for Thin-Strut DESolve Cx Novolimus Eluting Bioresorbable Coronary Scaffold System

Sunnyvale, CA —October 31, 2016—Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced today that a successful live case demonstration of its next-generation DESolve® NXT Plus Novolimus Eluting Bioresorbable Coronary Scaffold System was presented at the 28th annual Transcatheter Cardiovascular Therapeutics (TCT) meeting in Washington, DC. “This live demonstration presented […]